Cepheid-Logo
Informationen anfordern
Standort / Sprache

{{headingText}}

{{paragraphText}}

{{continueBtnLabel}}

{{initials}}
Main Menu
Standort / Sprache

{{headingText}}

{{paragraphText}}

{{continueBtnLabel}}

Informationen anfordern
Informationen anfordern

Xpert® Breast Cancer STRAT4

Order Now
STRAT4 computer generated depiction.

Standardisierte Bestimmung der Brustkrebs-Biomarker ESR1, PGR, ERBB2 und MKi67 auf mRNA-Ebene in weniger als zwei Stunden

Der Bedarf

an ill woman listens to a physician
Die Ergebnisse für die Brustkrebs-Biomarker ER/PGR/HER2/Ki-67 müssen verlässlich und objektiv sein.
  • Kliniker benötigen eine zuverlässigere Bestimmung von ER/PGR/HER2/Ki-67 in FFPE-Tumorgewebsproben.
  • 5 % der HER2-IHC-Ergebnisse sind gemäß der in den Leitlinien empfohlenen Einteilung fragwürdig.1
  • Die Bestätigung von unklaren HER2-IHC2+-Ergebnissen mit FISH ist aufwendig.1-4
  • Je nach verwendeter Technik und Anwender kann es bei ca. 20 % der ER- und PGR-Ergebnisse zu Ungenauigkeiten kommen.5
  • Ki-67-IHC-Scores variieren aufgrund fehlender Standardisierung stark.6
(1)Wolff AC et al. Recommendations for Human Epidermal Growth Factor Receptor
(2) Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. J Clin Oncol. 1. Nov. 2013;31(31):3997-4013.
(3)Starczynski J et al. HER2 Gene Amplification in Breast Cancer. A Rogues' Gallery of Challenging Diagnostic Cases: UKNEQAS Interpretation Guidelines and Research Recommendations. AM J Clin Pathol. 2012 Apr;137(4):595-605.
(4)Rakha A et al. Updated UK Recommendations for HER2 assessment in breast cancer. Clin Pathol. 2015 Feb;68(2):93-99.
(5)Hammond MEH et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. J Clin Onc. 2010 Feb 23; 28(16): 2784-2795.
(6) Borges PCC, Spencer HB, Barbosa C, Costa V, Furtado A, Leal MC, Lopes C, Ferreira D, Carvalho AL, Dos-Santos-Silva I, Santos LL. XPERT® breast cancer STRAT4 as an alternative method of identifying breast cancer phenotype in Cape Verde (preliminary results). Ecancermedicalscience. 2023 Apr 11;17:1530. doi: 10,3332/ ecancer.2023.1530. PMID: 37138965; PMCID: PMC10151082.

Die Lösung

a male and a female researchers scanning cepheid test cartridges
Xpert Breast Cancer STRAT4 supports standardized ER/PGR/HER2/Ki‑67 mRNA assessment in less than 2 hours.
  • Xpert Breast Cancer STRAT4 bietet eine semiquantitative Bestimmung der mRNA-Konzentration von ER, PGR, HER2 und Ki-67 in FFPE-Schnitten von invasivem Mammakarzinomgewebe.
    • CYFIP1* wird als Referenzgen zur Normalisierung der Ergebnisse verwendet.
    • Jeder Test enthält drei Kontrollen.
    • Der Ergebnisreport wird zur einfachen und objektiven Interpretation der Ergebnisse von einer Software generiert.
CYFIP1: Cytoplasmic FMR1 interacting protein 1

Der Vorteil

a smiling female doctor attends an elderly woman
  • Fast, clear, and accurate results by STRAT4 can help laboratories in diverse settings address various challenges with IHC/ISH testing to aid in the clinical evaluation of patients. 6
  • May facilitate a cost-efficient, quick, easy, and quality solution in labs facing challenges with IHC.7-9
  • Enables decentralized testing that doesn’t require a PCR laboratory to support breast cancer testing in low- and middle-income countries. 6.7.9
(6) Borges PCC, Spencer HB, Barbosa C, Costa V, Furtado A, Leal MC, Lopes C, Ferreira D, Carvalho AL, Dos-Santos-Silva I, Santos LL. XPERT® breast cancer STRAT4 as an alternative method of identifying breast cancer phenotype in Cape Verde (preliminary results). Ecancermedicalscience. 2023 Apr 11;17:1530. doi: 10,3332/ ecancer.2023.1530. PMID: 37138965; PMCID: PMC10151082.
(7) Marcellin Mugabe, Kenneth E Ho, Deo Ruhangaza, Dan Milner, Belson Rugwizangoga, Victor C Chu, Natalie C Wu, Annaliza Rizo, Jodi M Weidler, Wendy Wong, Michael Bates, Jane E Brock, Use of the Xpert Breast Cancer STRAT4 for Biomarker Evaluation in Tissue Processed in a Developing Country, American Journal of Clinical Pathology, Volume 156, Issue 5, November 2021, Pages 766–776, https://doi.org/10.1093/ajcp/aqab016
(8) El Aje, R, Naya A, Khoaja A, Zaid Y, Oudghiri M, Weidler J, and Karkouri M. A Study Comparing Immunohistochemistry, Fluorescence in situ hybridization, GeneXpert® Breast Cancer STRAT4 Assay for Determining Hormone Receptor, Human Epidermal Growth Factor Receptor 2, Ki67 Status in Invasive Breast Carcinomain Moroccan women. Progress in Microbes and Molecular Biology. 2023; 6, 1; a0000332. doi: 10.36877/pmmb.a0000332.
(9) Erfani P et al. Breast cancer molecular diagnostics in Rwanda: a cost-minimization study of immunohistochemistry versus a novel GeneXpert® mRNA expression assay. Bull World Health Organ 2023;101:10–19 | doi: http://dx.doi.org/10.2471/BLT.22.288800 The Impact The Need The Solution Breast cancer in women is the leading cancer worldwide, with approximately 2.3 million new breast cancer cases every year.

Bessere Ergebnisse erzielen

Informationen anfordern
Powered by Translations.com GlobalLink Web SoftwarePowered by GlobalLink Web